![PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts113/v4/ae/85/a4/ae85a473-ed8f-49c9-b109-e88019bd4bf8/mza_466067069700462642.jpg/100x100bb.jpg)
Nathan H. Fowler, MD - Building New Management Models for NHL Care: Tumor Board Insights on Innovative Therapeutics in FL and DLBCL
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
English - January 08, 2021 23:00 - 1 hour - ★★★★ - 8 ratingsScience cme medical education cme credits peerview insession inreview oncology hematology cne Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.